LAG3 and melanoma: Also, better insights into the impact of LAG-3 inhibition on effector T cells and other immune cell populations in the TME shall be a major priority across the melanoma immuno-oncology discipline and can help identify predictive biomarkers to evaluate response to treatment and identify patients who would most likely benefit from this combination therapy.